Report of Foreign Issuer (6-k)
May 01 2019 - 1:38PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of May, 2019
Commission
File Number 001-15170
GlaxoSmithKline plc
(Translation
of registrant's name into English)
980 Great West Road, Brentford, Middlesex, TW8
9GS
(Address
of principal executive office)
Indicate by check
mark whether the registrant files or will file annual reports under
cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ____
GlaxoSmithKline plc (the '
Company
')
Transaction notification
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
a)
|
Name
|
Sir Philip Hampton
|
b)
|
Position/status
|
Non-Executive Chairman
|
c)
|
Initial
notification /
amendment
|
Initial notification
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a)
|
Name
|
GlaxoSmithKline plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
a)
|
Description of thefinancial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
b)
|
Nature of the
transaction
|
Acquisition of notional Ordinary Shares under the share allocation
arrangements for Independent Non-Executive Directors for the period
of service from 1 January 2019 to 31 March 2019.
|
c)
|
Price(s) and
volume(s)
|
Price(s)
|
Volume(s)
|
£15.68
|
2,790.179
|
d)
|
Aggregated
information
Aggregated volume
Price
|
n/a (single transaction)
|
e)
|
Date
of the transaction
|
2019-05-01
|
f)
|
Place of the
transaction
|
n/a
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
a)
|
Name
|
Mr Vindi Banga
|
b)
|
Position/status
|
Senior Independent Non-Executive Director
|
c)
|
Initial
notification /
amendment
|
Initial notification
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a)
|
Name
|
GlaxoSmithKline plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
a)
|
Description of the
financial instrument
|
Ordinary shares of 25 pence each ('Ordinary
Shares')
ISIN: GB0009252882
|
b)
|
Nature of the
transaction
|
Acquisition of notional Ordinary Shares under the share allocation
arrangements for Independent Non-Executive Directors for the period
of service from 1 January 2019 to 31 March 2019.
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
£15.68
|
458.386
|
d)
|
Aggregated
information
Aggregated volume
Price
|
n/a (single transaction)
|
e)
|
Date
of the transaction
|
2019-05-01
|
f)
|
Place of the
transaction
|
n/a
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
a)
|
Name
|
Dr Vivienne Cox
|
b)
|
Position/status
|
Independent Non-Executive Director
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a)
|
Name
|
GlaxoSmithKline plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
a)
|
Description of the
financial instrument
|
Ordinary shares of 25 pence each ('Ordinary
Shares')
ISIN: GB0009252882
|
b)
|
Nature of the
transaction
|
Acquisition of notional Ordinary Shares under the share allocation
arrangements for Independent Non-Executive Directors for the period
of service from 1 January 2019 to 31 March 2019.
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
£15.68
|
338.807
|
d)
|
Aggregated
information
Aggregated volume
Price
|
n/a (single transaction)
|
e)
|
Date
of the transaction
|
2019-05-01
|
f)
|
Place of the
transaction
|
n/a
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
a)
|
Name
|
Ms Lynn Elsenhans
|
b)
|
Position/status
|
Independent Non-Executive Director
|
c)
|
Initial
notification /
amendment
|
Initial notification
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a)
|
Name
|
GlaxoSmithKline plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
a)
|
Description of the
financial instrument
|
American Depositary Shares ('ADSs')
ISIN: US37733W1053
|
b)
|
Nature of the
transaction
|
Acquisition of notional ADSs under the share allocation
arrangements for Independent Non-Executive Directors for the period
of service from 1 January 2019 to 31 March 2019.
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
$40.67
|
1,174.570
|
d)
|
Aggregated
information
Aggregated volume
Price
|
n/a (single transaction)
|
e)
|
Date
of the transaction
|
2019-05-01
|
f)
|
Place of the
transaction
|
n/a
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
a)
|
Name
|
Dr Laurie Glimcher
|
b)
|
Position/status
|
Independent Non-Executive Director
|
c)
|
Initial
notification /
amendment
|
Initial notification
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a)
|
Name
|
GlaxoSmithKline plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
a)
|
Description of the
financial instrument
|
American Depositary Shares ('ADSs')
ISIN: US37733W1053
|
b)
|
Nature of the
transaction
|
Acquisition of notional ADSs under the share allocation
arrangements for Independent Non-Executive Directors for the period
of service from 1 January 2019 to 31 March 2019.
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
$40.67
|
1,351.687
|
d)
|
Aggregated
information
Aggregated volume
Price
|
n/a (single transaction)
|
e)
|
Date
of the transaction
|
2019-05-01
|
f)
|
Place of the
transaction
|
n/a
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
a)
|
Name
|
Dr Jesse Goodman
|
b)
|
Position/status
|
Independent Non-Executive Director
|
c)
|
Initial
notification /
amendment
|
Initial notification
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a)
|
Name
|
GlaxoSmithKline plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
a)
|
Description of the
financial instrument
|
American Depositary Shares ('ADSs')
ISIN: US37733W1053
|
b)
|
Nature of the
transaction
|
Acquisition of notional ADSs under the share allocation
arrangements for Independent Non-Executive Directors for the period
of service from 1 January 2019 to 31 March 2019.
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
$40.67
|
407.837
|
d)
|
Aggregated
information
Aggregated volume
Price
|
n/a (single transaction)
|
e)
|
Date
of the transaction
|
2019-05-01
|
f)
|
Place of the
transaction
|
n/a
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
a)
|
Name
|
Ms Judy Lewent
|
b)
|
Position/status
|
Independent Non-Executive Director
|
c)
|
Initial
notification /
amendment
|
Initial notification
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a)
|
Name
|
GlaxoSmithKline plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
a)
|
Description of the
financial instrument
|
American Depositary Shares ('ADSs')
ISIN: US37733W1053
|
b)
|
Nature of the
transaction
|
Acquisition of notional ADSs under the share allocation
arrangements for Independent Non-Executive Directors for the period
of service from 1 January 2019 to 31 March 2019.
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
$40.67
|
454.447
|
d)
|
Aggregated
information
Aggregated volume
Price
|
n/a (single transaction)
|
e)
|
Date
of the transaction
|
2019-05-01
|
f)
|
Place of the
transaction
|
n/a
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
a)
|
Name
|
Mr Urs Rohner
|
b)
|
Position/status
|
Independent Non-Executive Director
|
c)
|
Initial
notification /
amendment
|
Initial notification
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a)
|
Name
|
GlaxoSmithKline plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
a)
|
Description of the
financial instrument
|
Ordinary shares of 25 pence each ('Ordinary
Shares')
ISIN: GB0009252882
|
b)
|
Nature of the
transaction
|
Acquisition of notional Ordinary Shares under the share allocation
arrangements for Independent Non-Executive Directors for the period
of service from 1 January 2019 to 31 March 2019.
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
£15.68
|
458.386
|
d)
|
Aggregated
information
Aggregated volume
Price
|
n/a (single transaction)
|
e)
|
Date
of the transaction
|
2019-05-01
|
f)
|
Place of the
transaction
|
n/a
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
GlaxoSmithKline plc
|
|
(Registrant)
|
|
|
Date: May
01, 2019
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
Victoria Whyte
|
|
Authorised
Signatory for and on
|
|
behalf
of GlaxoSmithKline plc
|
GSK (NYSE:GSK)
Historical Stock Chart
From Mar 2024 to Apr 2024
GSK (NYSE:GSK)
Historical Stock Chart
From Apr 2023 to Apr 2024